This report analyzes the worldwide markets for Molecular Diagnostics in US$ million by the following segments: Infectious Disease Testing, Pharmacogenomics, and Cancer Screening. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets. The report profiles 101 companies including many key and niche players such as Abbott Laboratories, Abbott Molecular, Applera Corporation, Celera, Biom
Innovative Clinical Chemistry and Immunodiagnostic Technologies and Emerging ...ReportLinker.com
This unique 1,115-page report contains 450 tables, and provides sales and market shares of leading reagent and instrument suppliers, as well as test volume and sales forecasts for 100 chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays, calibrators and controls. Available by country and section.This unique worldwide market intelligence and technology assessment report will help current suppliers and potential market entrants identify and evaluate emerging opportunities and develop effective strategic responses. The report explores future trends in the U.S., five major European countries (France, Germany, Italy, Spain, UK) and Japan; provides estimates of the specimen, test and sales volumes, as well as major suppliers’ sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next ten years.The clinical chemistry and immunodiagnostics markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments, like routine chemistry, begin to resemble commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace creates exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, and calibrators.
There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the clinic and also to lower its costs. Clinical labs experienced a substantial growth during the last decade. The emphasis in this TriMark Publications report is on those companies that are actively developing and marketing high-growth diagnostic testing technologies in the clinical hospital market. It defines the dollar volume of sales, both worldwide and in the U.S., of the market and analyzes the factors that influence the size and growth of market segments. The study goes on to discuss in detail trends that have developed which have stimulated this market, and also comments in detail patterns of information processing in the high-growth diagnostic testing technologies. Moreover, this exanimation provides an overview of the diagnostic testing market, including the latest information regarding exciting new products and industry trends. It will not only quantify but also qualify the market high-growth segments as an area of research and investment. Forecasts of the market and analyses of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category.
Global Psoriasis Pipeline Drugs Market Assessment – Forecast to 2023AzothAnalytics
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Psoriasis Pipeline Drugs Market by assessing the potential of the six drugs that will be launched in the near future. Also, the report assesses the results of various clinical trials undertaken for each of the six drugs, the product profile, description and regulatory phase of each of the six drugs. Also, 7Ps Analysis (Patent, Phase, Pathway, Patient, Physician, Payer, Partner) has been done for each of the six drugs to present the current perspective.
This report analyzes the worldwide markets for HIV/AIDS Testing in US$ Million by the following product segments: HIV/AIDS Screening Tests, HIV/AIDS Confirmatory Tests, and HIV/AIDS Monitoring Tests. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets.The report profiles 63 companies including many key and niche players such as Abbott Laboratories Inc., Abbott Molecular Inc., Adaltis S.r.l., Biom
5 Cutting-Edge Trends in Molecular DiagnosticsBruce Carlson
Despite the focus on novelty in this field, it is near 2 decades old. Yet a lot is changing. A look at a few trends that could change molecular diagnostics.
Future Clinical Chemistry and Immunodiagnostics Markets: Growth Opportunities...ReportLinker.com
During the next decade, the clinical chemistry and immunodiagnostics markets will undergo significant transformation. The changes will be caused convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments, like routine chemistry, will resemble commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others."The Clinical Chemistry and Immunodiagnostics Markets" is a unique worldwide market intelligence and technology assessment study designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities and develop effective strategic responses. The study explores future trends in the U.S., five major European countries and Japan; provides estimates of the specimen, test and sales volumes, as well as major suppliers' sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities facing suppliers during the next ten years.Contains 1,115 pages and 450 tables
Innovative Clinical Chemistry and Immunodiagnostic Technologies and Emerging ...ReportLinker.com
This unique 1,115-page report contains 450 tables, and provides sales and market shares of leading reagent and instrument suppliers, as well as test volume and sales forecasts for 100 chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays, calibrators and controls. Available by country and section.This unique worldwide market intelligence and technology assessment report will help current suppliers and potential market entrants identify and evaluate emerging opportunities and develop effective strategic responses. The report explores future trends in the U.S., five major European countries (France, Germany, Italy, Spain, UK) and Japan; provides estimates of the specimen, test and sales volumes, as well as major suppliers’ sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next ten years.The clinical chemistry and immunodiagnostics markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments, like routine chemistry, begin to resemble commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace creates exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, and calibrators.
There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the clinic and also to lower its costs. Clinical labs experienced a substantial growth during the last decade. The emphasis in this TriMark Publications report is on those companies that are actively developing and marketing high-growth diagnostic testing technologies in the clinical hospital market. It defines the dollar volume of sales, both worldwide and in the U.S., of the market and analyzes the factors that influence the size and growth of market segments. The study goes on to discuss in detail trends that have developed which have stimulated this market, and also comments in detail patterns of information processing in the high-growth diagnostic testing technologies. Moreover, this exanimation provides an overview of the diagnostic testing market, including the latest information regarding exciting new products and industry trends. It will not only quantify but also qualify the market high-growth segments as an area of research and investment. Forecasts of the market and analyses of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category.
Global Psoriasis Pipeline Drugs Market Assessment – Forecast to 2023AzothAnalytics
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Psoriasis Pipeline Drugs Market by assessing the potential of the six drugs that will be launched in the near future. Also, the report assesses the results of various clinical trials undertaken for each of the six drugs, the product profile, description and regulatory phase of each of the six drugs. Also, 7Ps Analysis (Patent, Phase, Pathway, Patient, Physician, Payer, Partner) has been done for each of the six drugs to present the current perspective.
This report analyzes the worldwide markets for HIV/AIDS Testing in US$ Million by the following product segments: HIV/AIDS Screening Tests, HIV/AIDS Confirmatory Tests, and HIV/AIDS Monitoring Tests. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets.The report profiles 63 companies including many key and niche players such as Abbott Laboratories Inc., Abbott Molecular Inc., Adaltis S.r.l., Biom
5 Cutting-Edge Trends in Molecular DiagnosticsBruce Carlson
Despite the focus on novelty in this field, it is near 2 decades old. Yet a lot is changing. A look at a few trends that could change molecular diagnostics.
Future Clinical Chemistry and Immunodiagnostics Markets: Growth Opportunities...ReportLinker.com
During the next decade, the clinical chemistry and immunodiagnostics markets will undergo significant transformation. The changes will be caused convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments, like routine chemistry, will resemble commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others."The Clinical Chemistry and Immunodiagnostics Markets" is a unique worldwide market intelligence and technology assessment study designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities and develop effective strategic responses. The study explores future trends in the U.S., five major European countries and Japan; provides estimates of the specimen, test and sales volumes, as well as major suppliers' sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities facing suppliers during the next ten years.Contains 1,115 pages and 450 tables
The global liquid biopsy market is projected to reach $12,933 million by 2030 and grow with a significant CAGR of 15.87%
get more detailed : https://bisresearch.com/industry-report/global-liquid-biopsy-market.html
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...ReportLinker.com
This new 900-page five-country market intelligence and technology assessment report from Venture Planning Group will help current suppliers and potential market entrants identify and evaluate emerging opportunities and develop effective strategic responses. The report explores future trends in major European countries (France, Germany, Italy, Spain, UK); provides estimates of the specimen, test and sales volumes, as well as major suppliers sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years.The clinical chemistry and immunodiagnostic markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. However, this evolving marketplace creates exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, and calibrators.
Competing in the European Molecular Diagnostics Market: France, Germany, Ital...ReportLinker.com
This new 970-page comprehensive five-country report from Venture Planning Group is designed to help current suppliers and potential market entrants identify and evaluate the major business opportunities emerging in the European molecular diagnostics market during the next five years. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.The $4.5 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of and cost-effective automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next five years.
Genome Editing Market Analysis By Technology (CRISPR, TALEN, ZFN), By Delivery Method (Ex-vivo, In-vivo), By Application (Animal/Plant Cell Editing), By Service (In-house, Outsourced), By End-use And Segment Forecasts, 2018 - 2025
There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the clinic and also to lower its costs. Clinical labs experienced a substantial growth during the last decade.
The 2011 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan&...ReportLinker.com
During the next decade, the clinical chemistry and immunodiagnostics markets will undergo significant transformation. The changes will be caused convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments, like routine chemistry, will resemble commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others."The Clinical Chemistry and Immunodiagnostics Markets" is a unique worldwide market intelligence and technology assessment study designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities and develop effective strategic responses. The study explores future trends in the U.S., five major European countries and Japan; provides estimates of the specimen, test and sales volumes, as well as major suppliers' sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities facing suppliers during the next ten years.Contains 1,115 pages and 450 tables
Scaffold Technology Market Size & Forecast, By Product (Hydrogels, Micro-Patterned Surface Microplates, Polymeric & Nanofiber Scaffold), By Application, By End-Use And Trend Analysis From 2018 To 2024
The U.S. medical plastics market is expected to reach almost 3.5 billion pounds by the end of 2010 and will grow at a compound annual growth rate (CAGR) of about 5%, consuming about 4.4 billion pounds by 2015.Commodity thermoplastics dominate the market with a little more than 55% of total volume. This sector is estimated at nearly 2 billion pounds in 2010 and should increase at a compound annual growth rate (CAGR) of 4.8% to reach 2.5 billion pounds in 2015.TPEs, engineering resins, and thermosets will show the most significant growth rates over the next 5 years although they only constitute about 20% of total volume. Of these, TPEs will experience the highest compound annual growth rate (CAGR) of 6.2%, from 68 million pounds in 2010 to 92 million pounds in 2015.
BIOSIMILARS - Regulation and Market Trends Joseph Pategou
Nowadays patients and physicians can have access to three types of drugs: a originators, a generic or a biosimilar.
Those drugs have different regulatory systems that apply in Europe; moreover the biosimilars regulation is evolving and may change. Regulation is an important factor that can give more confidence to patients and healthcare professionals. As a consequence, biosimilaires will grow.
Minimally invasive medical robotics, imaging & visualization systems & surgic...Ron Ethell
The MIS market is expected to grow at a fast rate with a CAGR of 8.2% and is expected to reach $35.5 billion by 2016. The surgical instruments segment commanded the larger share; i.e. 38.4%, of the global minimally invasive surgical devices market in 2011. This growth has been primarily attributed to the increased usage of these devices and instruments in MIS procedures. Devices such as guiding catheters and guidewires as well as balloons have been widely used in interventional angioplasty and peripheral extremity MIS procedures. Numerous innovations in the technologies of devices such as balloons have added to the growth in the market.
Currently worth a few million dollars, the emerging organs-on-chips market has the potential to become a multi-billion dollar market.
Organs-on-chips: the promise of solving one of the pharmaceutical industry’s major hurdles
Bringing a new drug to market is one of the longest and most costly paths any industry has to walk. Companies start with several thousands of compounds that may have positive effects against a disease or a human condition. More than twelve years and several billion dollars later, if they’re lucky they managed to get one of these compounds onto the market. All the others failed at one stage or another during the drug development process – and the later the failure, the more expensive it is. Current methods – cell culture in petri dishes and animal testing among others – are not predictive enough. Around 90% of drugs that have been validated on these models then fail during clinical trials because of toxicity or lack of efficacy. The pharmaceutical industry therefore needs more predictive tools to make drug candidates fail earlier and cheaper. Other industries where toxicity testing is a major concern, such as cosmetics, agro-food and consumer goods, also need such solutions, in particular because animal testing is now banned for these industries in certain geographical areas. Several options have been envisioned, the most promising of which is certainly organs-on-chips. These combinations of micro-technology and biology reconstitute the physiological and mechanical functions of human organs under the form of micro-engineered devices lined with living cells. Precisely controlled fluid flows combined with mechanical cues and tissue-tissue interfaces enable dynamic models, much more relevant than conventional static cell cultures. As a sign of confidence in this technology, significant funding has been allocated to organs-on-chips developers: DARPA and the NIH respectively awarded $140M and $76M over 5-year periods to support developments. In parallel, technology developers have raised more than $80M since 2012 with investors. In Yole Développement’s report, all the key elements to understand the organs-on-chips landscape are detailed.
For more information, please visit our website: https://www.i-micronews.com/reports.html
Global Cardiovascular Disease Diagnostics IndustryReportLinker.com
This report analyzes the worldwide markets for Cardiovascular Disease Diagnostics in US$ Million by the following product segments - Annual estimates and forecasts are provided for the period 2007 through 2015. Also, a seven-year historic analysis is provided for these markets. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, Middle East, and Latin America. The report profiles 71 companies including many key and niche players worldwide such as AccuTech, LLC, Abbott Diagnostics, Alere Inc., Biosite, Inc., Ani Biotech Oy, Axis-Shield PoC, Beckman Coulter, Inc., biom
Global Sterilization Systems & Equipment IndustryReportLinker.com
This report analyzes the worldwide markets for Sterilization Systems & Equipment in US$ Million by the following segments: Steam/Autoclave, Ethylene Oxide, Gas Plasma, Gamma Radiation, E-Beam Radiation, Other Methods, and Sterilization Supplies. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets. The report profiles 143 companies including many key and niche players such as 3M Company, Advanced Sterilization Products, Cantel Medical Corp, Minntech Corporation, Getinge AB, L3 Pulse Sciences, SteriGenics International, Inc., STERIS Corporation, TSO3, and Tuttnauer Company. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Cell-Based Assay Market 2022-2027: Size, Share, Trends, Analysis & Research ...IMARC Group
According to the latest report by IMARC Group, that the global cell-based assay market size reached US$ 18.9 Billion in 2021. Cell-based assay or cellular assay is an analytical method to determine the concentration of a substance by observing its effects on living organisms (in vivo) or tissues (in vitro). It provides a closer representation of the real-life model, which helps to verify the biological activity of drugs and determine whether the antibodies produced by the patient are neutralizing the drug.
The global liquid biopsy market is projected to reach $12,933 million by 2030 and grow with a significant CAGR of 15.87%
get more detailed : https://bisresearch.com/industry-report/global-liquid-biopsy-market.html
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...ReportLinker.com
This new 900-page five-country market intelligence and technology assessment report from Venture Planning Group will help current suppliers and potential market entrants identify and evaluate emerging opportunities and develop effective strategic responses. The report explores future trends in major European countries (France, Germany, Italy, Spain, UK); provides estimates of the specimen, test and sales volumes, as well as major suppliers sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years.The clinical chemistry and immunodiagnostic markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. However, this evolving marketplace creates exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, and calibrators.
Competing in the European Molecular Diagnostics Market: France, Germany, Ital...ReportLinker.com
This new 970-page comprehensive five-country report from Venture Planning Group is designed to help current suppliers and potential market entrants identify and evaluate the major business opportunities emerging in the European molecular diagnostics market during the next five years. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.The $4.5 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of and cost-effective automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next five years.
Genome Editing Market Analysis By Technology (CRISPR, TALEN, ZFN), By Delivery Method (Ex-vivo, In-vivo), By Application (Animal/Plant Cell Editing), By Service (In-house, Outsourced), By End-use And Segment Forecasts, 2018 - 2025
There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the clinic and also to lower its costs. Clinical labs experienced a substantial growth during the last decade.
The 2011 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan&...ReportLinker.com
During the next decade, the clinical chemistry and immunodiagnostics markets will undergo significant transformation. The changes will be caused convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments, like routine chemistry, will resemble commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others."The Clinical Chemistry and Immunodiagnostics Markets" is a unique worldwide market intelligence and technology assessment study designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities and develop effective strategic responses. The study explores future trends in the U.S., five major European countries and Japan; provides estimates of the specimen, test and sales volumes, as well as major suppliers' sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities facing suppliers during the next ten years.Contains 1,115 pages and 450 tables
Scaffold Technology Market Size & Forecast, By Product (Hydrogels, Micro-Patterned Surface Microplates, Polymeric & Nanofiber Scaffold), By Application, By End-Use And Trend Analysis From 2018 To 2024
The U.S. medical plastics market is expected to reach almost 3.5 billion pounds by the end of 2010 and will grow at a compound annual growth rate (CAGR) of about 5%, consuming about 4.4 billion pounds by 2015.Commodity thermoplastics dominate the market with a little more than 55% of total volume. This sector is estimated at nearly 2 billion pounds in 2010 and should increase at a compound annual growth rate (CAGR) of 4.8% to reach 2.5 billion pounds in 2015.TPEs, engineering resins, and thermosets will show the most significant growth rates over the next 5 years although they only constitute about 20% of total volume. Of these, TPEs will experience the highest compound annual growth rate (CAGR) of 6.2%, from 68 million pounds in 2010 to 92 million pounds in 2015.
BIOSIMILARS - Regulation and Market Trends Joseph Pategou
Nowadays patients and physicians can have access to three types of drugs: a originators, a generic or a biosimilar.
Those drugs have different regulatory systems that apply in Europe; moreover the biosimilars regulation is evolving and may change. Regulation is an important factor that can give more confidence to patients and healthcare professionals. As a consequence, biosimilaires will grow.
Minimally invasive medical robotics, imaging & visualization systems & surgic...Ron Ethell
The MIS market is expected to grow at a fast rate with a CAGR of 8.2% and is expected to reach $35.5 billion by 2016. The surgical instruments segment commanded the larger share; i.e. 38.4%, of the global minimally invasive surgical devices market in 2011. This growth has been primarily attributed to the increased usage of these devices and instruments in MIS procedures. Devices such as guiding catheters and guidewires as well as balloons have been widely used in interventional angioplasty and peripheral extremity MIS procedures. Numerous innovations in the technologies of devices such as balloons have added to the growth in the market.
Currently worth a few million dollars, the emerging organs-on-chips market has the potential to become a multi-billion dollar market.
Organs-on-chips: the promise of solving one of the pharmaceutical industry’s major hurdles
Bringing a new drug to market is one of the longest and most costly paths any industry has to walk. Companies start with several thousands of compounds that may have positive effects against a disease or a human condition. More than twelve years and several billion dollars later, if they’re lucky they managed to get one of these compounds onto the market. All the others failed at one stage or another during the drug development process – and the later the failure, the more expensive it is. Current methods – cell culture in petri dishes and animal testing among others – are not predictive enough. Around 90% of drugs that have been validated on these models then fail during clinical trials because of toxicity or lack of efficacy. The pharmaceutical industry therefore needs more predictive tools to make drug candidates fail earlier and cheaper. Other industries where toxicity testing is a major concern, such as cosmetics, agro-food and consumer goods, also need such solutions, in particular because animal testing is now banned for these industries in certain geographical areas. Several options have been envisioned, the most promising of which is certainly organs-on-chips. These combinations of micro-technology and biology reconstitute the physiological and mechanical functions of human organs under the form of micro-engineered devices lined with living cells. Precisely controlled fluid flows combined with mechanical cues and tissue-tissue interfaces enable dynamic models, much more relevant than conventional static cell cultures. As a sign of confidence in this technology, significant funding has been allocated to organs-on-chips developers: DARPA and the NIH respectively awarded $140M and $76M over 5-year periods to support developments. In parallel, technology developers have raised more than $80M since 2012 with investors. In Yole Développement’s report, all the key elements to understand the organs-on-chips landscape are detailed.
For more information, please visit our website: https://www.i-micronews.com/reports.html
Global Cardiovascular Disease Diagnostics IndustryReportLinker.com
This report analyzes the worldwide markets for Cardiovascular Disease Diagnostics in US$ Million by the following product segments - Annual estimates and forecasts are provided for the period 2007 through 2015. Also, a seven-year historic analysis is provided for these markets. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, Middle East, and Latin America. The report profiles 71 companies including many key and niche players worldwide such as AccuTech, LLC, Abbott Diagnostics, Alere Inc., Biosite, Inc., Ani Biotech Oy, Axis-Shield PoC, Beckman Coulter, Inc., biom
Global Sterilization Systems & Equipment IndustryReportLinker.com
This report analyzes the worldwide markets for Sterilization Systems & Equipment in US$ Million by the following segments: Steam/Autoclave, Ethylene Oxide, Gas Plasma, Gamma Radiation, E-Beam Radiation, Other Methods, and Sterilization Supplies. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets. The report profiles 143 companies including many key and niche players such as 3M Company, Advanced Sterilization Products, Cantel Medical Corp, Minntech Corporation, Getinge AB, L3 Pulse Sciences, SteriGenics International, Inc., STERIS Corporation, TSO3, and Tuttnauer Company. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Cell-Based Assay Market 2022-2027: Size, Share, Trends, Analysis & Research ...IMARC Group
According to the latest report by IMARC Group, that the global cell-based assay market size reached US$ 18.9 Billion in 2021. Cell-based assay or cellular assay is an analytical method to determine the concentration of a substance by observing its effects on living organisms (in vivo) or tissues (in vitro). It provides a closer representation of the real-life model, which helps to verify the biological activity of drugs and determine whether the antibodies produced by the patient are neutralizing the drug.
This report analyzes the worldwide markets for Imaging Agents in US$ Million by the following product segments - Contrast Media (X-Ray, MRI, & Ultrasound), and Diagnostic Radiopharmaceuticals. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. Also, a seven-year historic analysis is provided for these markets. The report profiles 55 companies including many key and niche players such as AMAG Pharmaceuticals Inc., Bayer Schering Pharma AG, Bracco Group, Covidien, Cytogen Corp., Daiichi Sankyo Company Limited, Eisai Co., Ltd, GE Healthcare, Guerbet Group, and Lantheus Medical Imaging. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Biomarkers are novel diagnostic tools that provide intelligence to physician about disease progression and treatment effects. Advancement in understanding of human genome promotes its application in diagnosis of disease on molecular basis. Biomarker technology is evidencing increased application in disease diagnosis, drug development and formulation, diagnosis for exposure of certain harmful chemical and prognostic treatments.
Veterinary Molecular Diagnostics Market PPT: Overview, Dynamics, Trends, Segm...IMARC Group
The global veterinary molecular diagnostics market size reached US$ 690.8 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,391.9 Million by 2032, exhibiting a growth rate (CAGR) of 7.9% during 2024-2032.
More Info:- https://www.imarcgroup.com/veterinary-molecular-diagnostics-market
This report analyzes the worldwide markets for Opthalmic Pharmaceutical Drugs in US$ million by the following Therapeutic Categories: Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets.The report profiles 95 companies including many key and niche players such as Akorn, Inc., Alcon, Inc., Allergan, Inc., Alimera Sciences, Inc., Bausch & Lomb, Inc., Genvec, Inc., GlaxoSmithKline Plc, Inspire Pharmaceuticals, Inc., ISTA Pharmaceuticals, Inc., Merck & Co., Inc., Novartis Ophthalmics, Opko Health, Inc., Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., QLT, Inc., Santen Pharmaceutical Co., and Santen Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Global Molecular Diagnostics Market: Innovative Technologies and Emerging Bus...ReportLinker.com
This unique seven-country report contains 1,050 pages, 96 tables, and is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the molecular diagnostics market during this decade. The report explores business and technological trends in the US, five major European countries, (France, Germany, Italy, Spain, UK) and Japan; provides 5- and 10-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next ten years.The molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next ten years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new DNA probe and biochip technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next ten years.
Monoclonal Antibodies Market PPT: Growth, Outlook, Demand, Keyplayer Analysis...IMARC Group
The global monoclonal antibodies market size reached US$ 207.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 307.8 Billion by 2028, exhibiting a growth rate (CAGR) of 6.9% during 2023-2028.
More Info:- https://www.imarcgroup.com/monoclonal-antibodies-market
Companion Diagnostics Market PPT: Growth, Outlook, Demand, Keyplayer Analysis...IMARC Group
The global companion diagnostics market size reached US$ 5.0 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 11.7 Billion by 2027, exhibiting a growth rate (CAGR) of 14.78% during 2022-2027.
More Info:- https://www.imarcgroup.com/companion-diagnostics-market
Veterinary Molecular Diagnostics Market by Product Type, Distribution Channel...IMARC Group
The global veterinary molecular diagnostics market size reached US$ 634.9 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,064.8 Million by 2028, exhibiting a growth rate (CAGR) of 8.8% during 2023-2028.
More Info:- https://www.imarcgroup.com/veterinary-molecular-diagnostics-market
Biotechnology Reagents Market PPT: Growth, Outlook, Demand, Keyplayer Analysi...IMARC Group
The global biotechnology reagents market size reached US$ 78,719 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 126,677 Million by 2028, exhibiting a growth rate (CAGR) of 8.50% during 2023-2028.
More Info:- https://www.imarcgroup.com/biotechnology-reagents-market
New technologies and the outsourcing of clinical trials to lower-cost countries will slow the recent annual increases in expenditures in the U.S. to a 3.3% compound annual growth rate (CAGR) over the forecast period.
Innovative Molecular Diagnostic Technologies and Emerging MarketsReportLinker.com
This unique seven-country report contains 1,050 pages, 96 tables, and is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the molecular diagnostics market during this decade. The report explores business and technological trends in the US, five major European countries, (France, Germany, Italy, Spain, UK) and Japan; provides 5- and 10-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next ten years.The molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next ten years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new DNA probe and biochip technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next ten years.
This report analyzes the worldwide markets for Nutraceuticals in US$ Million by the following Product Groups/Segments: Dietary Supplements (Vitamins, Minerals, Herbals, Non-Herbals, & Others), and Functional Foods. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. Also, a seven-year historic analysis is provided for these markets. The report profiles 295 companies including many key and niche players such as Archer Daniels Midland Company, Bactolac Pharmaceutical, Inc., BASF AG, BASF Human Nutrition, Bayer Healthcare AG, Bayer Consumer Care, Ceapro, Inc., GlaxoSmithKline Plc, Groupe Danone, Arkopharma Laboratories SA, Mead Johnson Nutritionals Inc., Natrol, Inc., Nestl
This report analyzes the worldwide markets for Nutricosmetics in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 59 companies including many key and niche players such as Borba, Inc., Carotech Bhd , Cognis, Denomega Nutritional Oils , Frutarom Industries Ltd., Ferrosan A/S, Frutels LLC , Functionalab, GliSODin Skin Nutrients, Husumer Mineralbrunnem HMB GmbH & Co. K.G, Inn
Organ-on-chip Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...IMARC Group
The global organ-on-chip market size reached US$ 61.6 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 541.8 Million by 2032, exhibiting a growth rate (CAGR) of 26.5% during 2024-2032.
More Info:- https://www.imarcgroup.com/organ-on-chip-market
Similar to Global Molecular Diagnostics Industry (20)
Smartphones: When is the first and last time you check yours?ReportLinker.com
Nearly half (46%) of Americans say they check their smartphones as soon as they wake up, while they’re still in bed, according to ReportLinker’s survey results. This is especially true of Millennials, 66% of whom say it’s the first thing they do before getting out of bed.
75% of Ameircans say they keep their smartphones active all day and night, and a staggering 83% of Millennials say they do.
In fact, disconnecting can be hard. More than half of Americans say their last check is right before bed – and 13% say they disconnect only after they’ve gotten into bed for the night. Even after they fall asleep, about 10% say they’ll wake up and check it during the night.
This graphic shows Samsung's customers are still loyal: 86% of Samsung Customers would consider Samsung next time they upgrade their smartphone. More info on reportlinker.com/inisght
Allegra Strategies is proud to release the 2012 report on European branded coffee shop market, providing comprehensive research on this fast developing market.The ProjectCaf
Allegra's definitive annual study on the UK branded coffee shop market is now available; with insight from over 25,000 consumers the report provides an authoritative view of the market.Drawing on more than 12 years in-depth research, it is considered to be the bible of the coffee sector.KEY AREAS COVERED' Market size and growth projections for the total UK market' Impact of recent economic downturn on trading performance' Key player profiles, including financial performance, pricing analysis and forecasts' Importance of ethical and sustainability issues' Key success factors and market trends' Opportunities and challenges for suppliers' Consumer coffee consumption patterns' Consumer brand awareness and perceptions of key players' Differences between customer demographics, including age, gender, occupation and location by the reportSOURCE OF INFORMATION' Interviews with CEOs, managing directors, senior managers and store managers of major industry players, including:' leading UK coffee and food-focused chains' major coffee roasters and key equipment suppliers' non-specialist players including department stores, supermarkets, bookstores' leading property companies, letting agents and landlords' local authorities' Online surveys with UK coffee shop visitors' Desk research including: News articles and trade press, the Internet and company websites,industry associations, published accounts, data supplied by operators' In-store observations and analysis
Wireless Infrastructure: Market Shares, Strategies, and Forecasts, Worldwide,...ReportLinker.com
WinterGreen Research announces that it has published a new study Wireless Infrastructure: Market Shares, Strategy, and Forecasts, Worldwide, 2013 to 2019. Next generation mission critical systems are leveraging new technology. The 2013 study has 554 pages, 245 tables and figures. Worldwide Wireless Infrastructure markets are poised to achieve significant growth as Building out core networks and backhaul for smart phones.A smart phone is not very smart if the infrastructure can't support its applications. In response to the high growth smart phone markets, wireless infrastructure promises to grow dramatically in the near term.. Wireless Infrastructure technologies include WiMax, LTE, 4G and HSPA. These technologies are driving much higher capacity from the base station back to the fiber core. Fiber core is putting extreme pressure on provider's infrastructure and backhaul networks.WinterGreen Research predicts that the dramatic growth of wireless infrastructure is based on the growth of smart phones to a one trillion market by 2019, serving an installed base of 8.5 billion, many people having more than one smart phone. Wireless infrastructure markets at $58 billion in 2012 will be $163 billion by 2019, new markets evolved because of the value that apps provide to smart phones, mobile devices, tablets, and the Internet of things.According to Susan Eustis, lead author of the study, 'Wireless Infrastructure is being installed to upgrade core networks and upgrade backhaul and base stations to make systems more modern. Infrastructure for the Internet and for smart mobile devices creates demand for more sophisticated web development and web applications that in turn depend on more sophisticated infrastructure. Everything is going mobile. This evolution is driven by mobile smart phones and tablets that provide universal connectivity. Modern systems represent a significant aspect of Internet market evolution.'The proportions of wireless infrastructure market industry segments are expected to remain much as they are, with the small cells and femtocells achieving strong growth on the access side, the core infrastructure must be upgraded to support the added backhaul backbone infrastructure. Wireless apps are expected to achieve $37 trillion revenue by 2019. This unbelievable growth occurs as the Internet is expanded to implement the interconnection of everything.Digital devices proliferate, machine to machine capabilities vastly expand instrumentation. The digital devices become the engine of a world economy, with apps collecting pennies a day for millions of apps from 8.5 billion people with smart phones by 2019.
Global Electric Resistance Welded Pipes IndustryReportLinker.com
This report analyzes the worldwide markets for Electric Resistance Welded Pipes in Thousand Tons by the following Product Segments: Mechanical Steel Tubing, Structural Tubing, Structural Steel Pipes, Pressure Tubing, Standard Pipes, Oil Country Tubular Goods, and Line Pipes. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 181 companies including many key and niche players such as Al Jazeera Steel Products Company SAOG, Arabian Pipes Company, ArcelorMittal SA, ERW Pipes Portfolio of ArcelorMittal ChelPipe, Choo Bee Metal Industries Berhad, EVRAZ North America, JFE Steel Corporation, Maharashtra Seamless Limited, Melewar Industrial Group Berhad, Nippon Steel & Sumitomo Metal Corporation, Northwest Pipe Company, OAO TMK, TMK IPSCO, PT Bakrie Pipe Industries, Salzgitter Mannesmann Line Pipe GmbH, Tata Steel Europe, Techint Group SpA, Tenaris S.A., TenarisSiderca, Ternium S.A., United States Steel Corporation, United Metallurgical Company /OMK, Welspun Corp Ltd., Wheatland Tube Company, and Select Products of Wheatland Tube Company. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
This report analyzes the worldwide markets for Wireless Gaming in US$ Million by the following Product Segments: Messaging Based Wireless Gaming, Browser/Web Based Wireless Gaming, and Downloadable Wireless Gaming. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. The report profiles 90 companies including many key and niche players such as Blockdot, Inc., DeNA Co., Ltd., Electronic Arts, Inc., Gameloft SA,GAMEVIL, GREE International, Inc., Glu Mobile Inc., GigaMedia Limited, HandyGames, I-play, Itsmy
Hyperalgesia Global Clinical Trials Review, H1, 2013ReportLinker.com
Hyperalgesia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Hyperalgesia Global Clinical Trials Review, H1, 2013" provides data on the Hyperalgesia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hyperalgesia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hyperalgesia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Genital Herpes Global Clinical Trials Review, H1, 2013ReportLinker.com
Genital Herpes Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Genital Herpes Global Clinical Trials Review, H1, 2013" provides data on the Genital Herpes clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Genital Herpes. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Genital Herpes. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
The Future of Direct Communications Technologies and Proximity-based Applicat...ReportLinker.com
Overview: There are a number of technologies that may be deployed that all provide the ability for devices to "discover" one another, although over different distances ranging from centimeters (Near Field Communications), to meters (Bluetooth), to 10s of meters (Wi-Fi). They also all provide the ability for the devices to communicate directly with one another without a centralized network. Some of these use direct communication as their primary mode of communication e.g. NFC or RFID. Others are more traditional networks which provide direct communication ability as an adjunct to their primary network functions e.g. LTE-Direct or Wi-Fi Direct. Most of the short-term drivers for proximity-based services will be mobile advertising and social networking, especially friend-finder services or dating services, and gaming. In the longer term, other applications will come into play within the scope of the so called Internet of Things. The challenge and opportunity for network operators will be to develop new user scenarios and even new business models to generate revenues from these services. This research uncovers opportunities that will be both beneficial and disruptive to the existing ecosystem and value chain. This research is must reading for any company that is considering offerings within proximity and direct communications and any company that wants to stay ahead of the crowd in terms of preparation for these disruptive technologies. Target Audience: ' Mobile network operators' Industry verticals of all types' Wireless device manufacturers' Network infrastructure companies' Advertising agencies, brands, and merchants' Social networks, advertising, and content providers' Proximity, location, and direct communications vendors Key Report Benefits: ' Market forecasts for each significant technology/solution approach' Recognize the upcoming role and importance of LTE Direct compared to other solutions' Analysis of the major vendors focused on proximity and direct communications solutions' Understand the relationship between proximity, direct communications and the Internet of Things' Understand the technical and business-related differences between proximity/presence and location' Identify each of the major technologies/solutions for proximity detection, location determination, and direct communications' Evaluation of the market for major applications including public safety, social networking, advertising, the Internet of Things, and general location services Select Companies in Report: ' 3M Company' Alcatel-Lucent' iSIGN' LG' Nokia' Samsung' Qualcomm' Verizon Wireless
Bradycardia Global Clinical Trials Review, H1, 2013ReportLinker.com
Bradycardia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Bradycardia Global Clinical Trials Review, H1, 2013" provides data on the Bradycardia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bradycardia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bradycardia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013" provides data on the Acid Indigestion / Heartburn/ Pyrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acid Indigestion / Heartburn/ Pyrosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Acid Indigestion / Heartburn/ Pyrosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
The biomass market suffered during the economic downturn in the face of low coal prices, logistic barriers and supply issues. 2010 saw more movement in the sector as coal prices are beginning to rise once again making co-firing coal plants with biomass more attractive. Furthermore, the biomass component of a coal-fired plant may be eligible for feed-in tariff or count towards renewable portfolio standards.Most of these plants rely on wood pellets, often transported at great distance, rather than wood chips or other less dense biomass sources. In the wood pellets market, supplies from the US and Canada are cheaper than their European counterparts and thus North America is a major suppli- ers for European biomass plants. CIS countries, Russia, Australia and South Africa have entered as significant suppliers, which if they could ramp up supply, could be serious competitors to the US and Canada. Or in the case of Russia, resolve supply delay issues, could be one of the biggest players in the market.
"𝑩𝑬𝑮𝑼𝑵 𝑾𝑰𝑻𝑯 𝑻𝑱 𝑰𝑺 𝑯𝑨𝑳𝑭 𝑫𝑶𝑵𝑬"
𝐓𝐉 𝐂𝐨𝐦𝐬 (𝐓𝐉 𝐂𝐨𝐦𝐦𝐮𝐧𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬) is a professional event agency that includes experts in the event-organizing market in Vietnam, Korea, and ASEAN countries. We provide unlimited types of events from Music concerts, Fan meetings, and Culture festivals to Corporate events, Internal company events, Golf tournaments, MICE events, and Exhibitions.
𝐓𝐉 𝐂𝐨𝐦𝐬 provides unlimited package services including such as Event organizing, Event planning, Event production, Manpower, PR marketing, Design 2D/3D, VIP protocols, Interpreter agency, etc.
Sports events - Golf competitions/billiards competitions/company sports events: dynamic and challenging
⭐ 𝐅𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐬:
➢ 2024 BAEKHYUN [Lonsdaleite] IN HO CHI MINH
➢ SUPER JUNIOR-L.S.S. THE SHOW : Th3ee Guys in HO CHI MINH
➢FreenBecky 1st Fan Meeting in Vietnam
➢CHILDREN ART EXHIBITION 2024: BEYOND BARRIERS
➢ WOW K-Music Festival 2023
➢ Winner [CROSS] Tour in HCM
➢ Super Show 9 in HCM with Super Junior
➢ HCMC - Gyeongsangbuk-do Culture and Tourism Festival
➢ Korean Vietnam Partnership - Fair with LG
➢ Korean President visits Samsung Electronics R&D Center
➢ Vietnam Food Expo with Lotte Wellfood
"𝐄𝐯𝐞𝐫𝐲 𝐞𝐯𝐞𝐧𝐭 𝐢𝐬 𝐚 𝐬𝐭𝐨𝐫𝐲, 𝐚 𝐬𝐩𝐞𝐜𝐢𝐚𝐥 𝐣𝐨𝐮𝐫𝐧𝐞𝐲. 𝐖𝐞 𝐚𝐥𝐰𝐚𝐲𝐬 𝐛𝐞𝐥𝐢𝐞𝐯𝐞 𝐭𝐡𝐚𝐭 𝐬𝐡𝐨𝐫𝐭𝐥𝐲 𝐲𝐨𝐮 𝐰𝐢𝐥𝐥 𝐛𝐞 𝐚 𝐩𝐚𝐫𝐭 𝐨𝐟 𝐨𝐮𝐫 𝐬𝐭𝐨𝐫𝐢𝐞𝐬."
Unveiling the Secrets How Does Generative AI Work.pdfSam H
At its core, generative artificial intelligence relies on the concept of generative models, which serve as engines that churn out entirely new data resembling their training data. It is like a sculptor who has studied so many forms found in nature and then uses this knowledge to create sculptures from his imagination that have never been seen before anywhere else. If taken to cyberspace, gans work almost the same way.
Remote sensing and monitoring are changing the mining industry for the better. These are providing innovative solutions to long-standing challenges. Those related to exploration, extraction, and overall environmental management by mining technology companies Odisha. These technologies make use of satellite imaging, aerial photography and sensors to collect data that might be inaccessible or from hazardous locations. With the use of this technology, mining operations are becoming increasingly efficient. Let us gain more insight into the key aspects associated with remote sensing and monitoring when it comes to mining.
Skye Residences | Extended Stay Residences Near Toronto Airportmarketingjdass
Experience unparalleled EXTENDED STAY and comfort at Skye Residences located just minutes from Toronto Airport. Discover sophisticated accommodations tailored for discerning travelers.
Website Link :
https://skyeresidences.com/
https://skyeresidences.com/about-us/
https://skyeresidences.com/gallery/
https://skyeresidences.com/rooms/
https://skyeresidences.com/near-by-attractions/
https://skyeresidences.com/commute/
https://skyeresidences.com/contact/
https://skyeresidences.com/queen-suite-with-sofa-bed/
https://skyeresidences.com/queen-suite-with-sofa-bed-and-balcony/
https://skyeresidences.com/queen-suite-with-sofa-bed-accessible/
https://skyeresidences.com/2-bedroom-deluxe-queen-suite-with-sofa-bed/
https://skyeresidences.com/2-bedroom-deluxe-king-queen-suite-with-sofa-bed/
https://skyeresidences.com/2-bedroom-deluxe-queen-suite-with-sofa-bed-accessible/
#Skye Residences Etobicoke, #Skye Residences Near Toronto Airport, #Skye Residences Toronto, #Skye Hotel Toronto, #Skye Hotel Near Toronto Airport, #Hotel Near Toronto Airport, #Near Toronto Airport Accommodation, #Suites Near Toronto Airport, #Etobicoke Suites Near Airport, #Hotel Near Toronto Pearson International Airport, #Toronto Airport Suite Rentals, #Pearson Airport Hotel Suites
Memorandum Of Association Constitution of Company.pptseri bangash
www.seribangash.com
A Memorandum of Association (MOA) is a legal document that outlines the fundamental principles and objectives upon which a company operates. It serves as the company's charter or constitution and defines the scope of its activities. Here's a detailed note on the MOA:
Contents of Memorandum of Association:
Name Clause: This clause states the name of the company, which should end with words like "Limited" or "Ltd." for a public limited company and "Private Limited" or "Pvt. Ltd." for a private limited company.
https://seribangash.com/article-of-association-is-legal-doc-of-company/
Registered Office Clause: It specifies the location where the company's registered office is situated. This office is where all official communications and notices are sent.
Objective Clause: This clause delineates the main objectives for which the company is formed. It's important to define these objectives clearly, as the company cannot undertake activities beyond those mentioned in this clause.
www.seribangash.com
Liability Clause: It outlines the extent of liability of the company's members. In the case of companies limited by shares, the liability of members is limited to the amount unpaid on their shares. For companies limited by guarantee, members' liability is limited to the amount they undertake to contribute if the company is wound up.
https://seribangash.com/promotors-is-person-conceived-formation-company/
Capital Clause: This clause specifies the authorized capital of the company, i.e., the maximum amount of share capital the company is authorized to issue. It also mentions the division of this capital into shares and their respective nominal value.
Association Clause: It simply states that the subscribers wish to form a company and agree to become members of it, in accordance with the terms of the MOA.
Importance of Memorandum of Association:
Legal Requirement: The MOA is a legal requirement for the formation of a company. It must be filed with the Registrar of Companies during the incorporation process.
Constitutional Document: It serves as the company's constitutional document, defining its scope, powers, and limitations.
Protection of Members: It protects the interests of the company's members by clearly defining the objectives and limiting their liability.
External Communication: It provides clarity to external parties, such as investors, creditors, and regulatory authorities, regarding the company's objectives and powers.
https://seribangash.com/difference-public-and-private-company-law/
Binding Authority: The company and its members are bound by the provisions of the MOA. Any action taken beyond its scope may be considered ultra vires (beyond the powers) of the company and therefore void.
Amendment of MOA:
While the MOA lays down the company's fundamental principles, it is not entirely immutable. It can be amended, but only under specific circumstances and in compliance with legal procedures. Amendments typically require shareholder
India Orthopedic Devices Market: Unlocking Growth Secrets, Trends and Develop...Kumar Satyam
According to TechSci Research report, “India Orthopedic Devices Market -Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030”, the India Orthopedic Devices Market stood at USD 1,280.54 Million in 2024 and is anticipated to grow with a CAGR of 7.84% in the forecast period, 2026-2030F. The India Orthopedic Devices Market is being driven by several factors. The most prominent ones include an increase in the elderly population, who are more prone to orthopedic conditions such as osteoporosis and arthritis. Moreover, the rise in sports injuries and road accidents are also contributing to the demand for orthopedic devices. Advances in technology and the introduction of innovative implants and prosthetics have further propelled the market growth. Additionally, government initiatives aimed at improving healthcare infrastructure and the increasing prevalence of lifestyle diseases have led to an upward trend in orthopedic surgeries, thereby fueling the market demand for these devices.
Discover the innovative and creative projects that highlight my journey throu...dylandmeas
Discover the innovative and creative projects that highlight my journey through Full Sail University. Below, you’ll find a collection of my work showcasing my skills and expertise in digital marketing, event planning, and media production.
The world of search engine optimization (SEO) is buzzing with discussions after Google confirmed that around 2,500 leaked internal documents related to its Search feature are indeed authentic. The revelation has sparked significant concerns within the SEO community. The leaked documents were initially reported by SEO experts Rand Fishkin and Mike King, igniting widespread analysis and discourse. For More Info:- https://news.arihantwebtech.com/search-disrupted-googles-leaked-documents-rock-the-seo-world/
Affordable Stationery Printing Services in Jaipur | Navpack n PrintNavpack & Print
Looking for professional printing services in Jaipur? Navpack n Print offers high-quality and affordable stationery printing for all your business needs. Stand out with custom stationery designs and fast turnaround times. Contact us today for a quote!
RMD24 | Retail media: hoe zet je dit in als je geen AH of Unilever bent? Heid...BBPMedia1
Grote partijen zijn al een tijdje onderweg met retail media. Ondertussen worden in dit domein ook de kansen zichtbaar voor andere spelers in de markt. Maar met die kansen ontstaan ook vragen: Zelf retail media worden of erop adverteren? In welke fase van de funnel past het en hoe integreer je het in een mediaplan? Wat is nu precies het verschil met marketplaces en Programmatic ads? In dit half uur beslechten we de dilemma's en krijg je antwoorden op wanneer het voor jou tijd is om de volgende stap te zetten.
Cracking the Workplace Discipline Code Main.pptxWorkforce Group
Cultivating and maintaining discipline within teams is a critical differentiator for successful organisations.
Forward-thinking leaders and business managers understand the impact that discipline has on organisational success. A disciplined workforce operates with clarity, focus, and a shared understanding of expectations, ultimately driving better results, optimising productivity, and facilitating seamless collaboration.
Although discipline is not a one-size-fits-all approach, it can help create a work environment that encourages personal growth and accountability rather than solely relying on punitive measures.
In this deck, you will learn the significance of workplace discipline for organisational success. You’ll also learn
• Four (4) workplace discipline methods you should consider
• The best and most practical approach to implementing workplace discipline.
• Three (3) key tips to maintain a disciplined workplace.
1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Global Molecular Diagnostics Industry
Published on October 2010
Report Summary
This report analyzes the worldwide markets for Molecular Diagnostics in US$ million by the following segments: Infectious Disease
Testing, Pharmacogenomics, and Cancer Screening. The report provides separate comprehensive analytics for the US, Canada,
Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A
seven-year historic analysis is also provided for these markets. The report profiles 101 companies including many key and niche
players such as Abbott Laboratories, Abbott Molecular, Applera Corporation, Celera, Biomérieux, CytoCore Inc., ELITech Group, GE
Healthcare, Gen-Probe Inc., Genzyme Corporation, Genzyme Genetics, MiraiBio, Inc., Novartis Vaccines & Diagnostics, Inc.,
QIAGEN N. V, Quest Diagnostics, Inc., Roche Diagnostics, Siemens Healthcare Diagnostics, and Tecan Group Ltd. Market data and
analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported
select online sources.
Table of Content
MOLECULAR DIAGNOSTICS MCP-1226
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Data Interpretation & Reporting Level 3
Quantitative Techniques & Analytics 3
Product Definitions and Scope of Study 3
Infectious Diseases Testing 4
Pharmacogenomics 4
Cancer Screening 4
2. INDUSTRY OVERVIEW 5
Global Market Outlook 5
Molecular Diagnostics - The Fastest Growing Medical
Diagnostic Technology 5
Current and Future Analysis 5
Growth Opportunities Abound Molecular Diagnostics Arena 6
Market for Molecular Diagnostics - An Introduction 6
Opportunities Galore for Market Participants 7
Global Molecular Diagnostics Industry Page 1/21
2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
New Applications Hold Promising Potential 7
Automated Systems - Prime Target 7
Infectious Disease Testing Drives the Diagnostics Market 8
The Future in Store 8
3. A REVIEW OF MEDICAL DIAGNOSTICS MARKET 9
Clinical Diagnostics Industry - Trends and Tendencies 9
Table 1: Worldwide In Vitro Diagnostics (IVD) Market by Major
Players (2009) -Market Share Breakdown by Value Sales for
Roche Diagnostics, Abbott Laboratories, Ortho/ Lifescan,
Bayer/Siemens, Beckman Coulter, Becton Dickinson, Dade
Behring/Siemens, BioMerieux, Bio-Rad, and Others (includes
corresponding Graph/Chart) 10
Table 2: Worldwide In Vitro Diagnostics (IVD) Market (2008)-
Percentage Breakdown by Value Sales for Immunochemistry,
Diabetes, Clinical Chemistry, Point-of-care testing,
Molecular Diagnostics, Hematology, Coagulation, and Others
(includes corresponding Graph/Chart) 10
Table 3: Worldwide Molecular Diagnostics Market by Leading
Players (2006 - A Recent Past Perspective) - Market Share
Breakdown by Value Sales for Roche Diagnostics, Chiron, Bayer
Diagnostics, GenProbe, Abbott Laboratories, Becton Dickinson,
and Others (includes corresponding Graph/Chart) 11
Diagnostic Tests - Classification 11
Table 4: Worldwide Genetic Testing Market by Leading Players
(2006 - A Recent Past Perspective) - Market Share Breakdown
by Value Sales for Roche Diagnostics/Affymetrix, Abbott
Laboratories, Bio-Rad Laboratories, and Others (includes
corresponding Graph/Chart) 12
Nucleic Acid Diagnostics Market - An Overview 12
Molecular Diagnostics - Growth Drivers 13
Molecular Diagnostics - A Replacement and Enabling Technology 14
Molecular Diagnostics for Lymphoid Malignancies 14
4. COMPETITIVE DYNAMICS IN THE MOLECULAR DIAGNOSTICS MARKET 15
Key Players and Their Technologies 15
The Top Tier 15
Mid-Sized and Small Companies 15
5. MARKET TRENDS & ISSUES 17
Market Consolidations on the Way to Integrate in Vivo and in
Vitro Diagnostics 17
Global Molecular Diagnostics on High Growth Curve 17
Pharmaceutical Firms Carving Their Niche in Molecular
Diagnostic Market 17
Towards Tailoring the Right Treatment for the Right Disease 17
Disease-Specific Molecular Diagnostics to Deliver Improved
Clinical Outcomes 18
Global Molecular Diagnostics Industry Page 2/21
3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Molecular Diagnostics and Intellectual Property 18
Business Opportunities in the Offing 18
Challenges Facing the Molecular Diagnostic Market 19
Medical Training and Practice Challenges 19
Shortcomings to Overcome 20
Limited Reimbursements by Third Party Payers - A Stumbling Block 20
Hurdles All the Way for Companies Eyeing Molecular Diagnostics 20
Product Marketing - Key to Commercial Success 21
Integration of Molecular Diagnostics into Therapeutics 21
Molecular Diagnostics - Moving from Centralization to
Decentralization 22
Migrating to Decentralized Format 22
Going Ahead with Decentralization 23
6. PRODUCT & TECHNOLOGY OVERVIEW 24
Molecular Diagnostics - Definition & Scope 24
Molecular Diagnostics - Impact on Healthcare 24
Utility of Molecular Diagnostic Tests 25
Background of Molecular Diagnostics 25
Major Molecular Diagnostics Products 25
Major Test Launches in Molecular Diagnostics in the Recent Past 26
Unabated Developments in Molecular Diagnostics Technology 26
Signal Amplification Technologies 27
PCR - New Developments 27
Major Applications of Real-Time PCR 27
Quantitative Real-Time PCR for Molecular Diagnostics 27
Signal Detection and Quantification 28
Quantitative Real-Time RT-PCR Analysis 28
Applications of Quantitative Real-Time PCR Analysis 28
Non-PCR Methods 28
Other Signal Amplification Technologies 29
DNA Probe Based Products 29
Direct Detection of Specific Nucleic Acid Sequences 29
Nucleic Acid Amplification and Detection 29
DNA Sequencing and Gene Detection 30
Arrays of Immobilized Probes (DNA Chips) in Gene Detection 30
RNA Diagnostics 31
Complementary Molecular Diagnostic Technologies 31
Fluorescent in situ hybridization (FISH) 31
DNA Biochips / Microarrays 32
Biosensors 33
Proteomic Technologies for Molecular Diagnostics 33
Nanotechnology for Molecular Diagnostics 33
Technologies on the Anvil 34
Haplotype Analysis - A Distant Possibility 34
Chronic Multi-Gene Defects Now Diagnosable 34
7. AN INSIGHT INTO APPLICATIONS OF MOLECULAR DIAGNOSTICS 35
Infectious Diseases Testing 35
Activity in the Field 35
Global Molecular Diagnostics Industry Page 3/21
4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Identifying Multidrug Resistance 36
Infectious Disease Treatment Monitoring 36
Other Infectious Diseases Applications 36
Genetic Disease Testing Applications 36
Pharmacogenomics - Prognosis Based on Genomics 37
Cancer Screening & Diagnosis 38
Molecular Tests Lead the Way for Cancer IVD Market Growth 39
Table 5: Worldwide Cancer Diagnostic Testing Market (2006 -
A Recent Past Review): Percentage Breakdown of Value Sales
for Immunoassays, Histology (IHC/ISH), Pap Testing, Flow
Cytometry, Prostate-Specific Antigen, Molecular Assays, and
Fecal Occult Blood Test (includes corresponding Graph/Chart) 39
Other Testing Applications 40
8. PRODUCT DEVELOPMENTS/ INTRODUCTIONS 41
Life Technologies Unveils ViralSEQTM Vesivirus Detection Kit 41
Applied Biosystems New Forensic DNA Kits 41
Quest Diagnostics Launches ColoVantage' Test 41
QIAGEN Introduces CE-labeled KRAS Kit 42
Roche Introduces Cobas 4800 42
bioMérieux Launches Upgraded Version of NucliSENS EasyQ®
Influenza A/B Test 43
bioMérieux Introduces NucliSENS EasyQ® MRSA 43
Roche Launches AMPLILINK 3.3 Series Software and cobas p 630
Instrument 43
Applied Biosystems Unveils 3500 Series and 3500 DX Series
Genetic Analyzer 44
Prometheus Laboratories Introduces New Range of Cancer
Diagnostic Products 44
Sequenom Introduces SensiGene Cystic Fibrosis Carrier
Screening Test 45
Triplex and MedMira to Unveil New Rapid Tests 45
Applied Biosystems to Introduce New Range of TaqMan® PCR Assays 45
Quest Diagnostics Unveils HIV-1 Coreceptor Tropism Test 46
Luminex introduced New Range of Cystic Fibrosis Tests 46
bioMérieux Introduces VIDAS® EBV Test 46
Luminex Unveils Two Novel Cystic Fibrosis Tests 47
MEDomics Launches MitoDx' for Diagnosing Mitochondrial Diseases 47
Exagen Diagnostics Unveils eXaIBStest and eXaIBD Blood Tests 48
bioMérieux Introduces NucliSENS EasyQ® HIV-1 v2.0 Test 48
PreAnalytiX Introduces PAXgene® Blood miRNA Kit 48
ViraCor Laboratories Introduces New JCV Test 48
ViraCor Laboratories Rolls Out JC Virus Detection Test 49
Focus Diagnostics Laboratory Introduces PCR Test 49
Siemens Launches CLINITEK AUWi Urine Analyzing System 49
Ocimum Biosolutions to Introduce New H1N1 Virus Detection Test 50
Myriad Genetics Introduces OnDose for Cancer Diagnosis 50
Applied Biosystems Introduces TaqMan® Array Gene Signature Plates 50
GeneNews to Develop Blood-Based Diagnostic Tests 51
Seegene Rolls Out Seeplex® Diarrhea ACE Detection Test 51
Global Molecular Diagnostics Industry Page 4/21
5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Seegene Unveils Seeplex® Meningitis ACE Detection test 51
Cepheid Introduces Xpert MRSA/SA Nasal Diagnostic Test 52
Roche to Launch LightCycler Test 52
Xenomics Unveils New Technology for Analyzing In Vivo Cell Death 52
bioMerieux Unveils NucliSENS EasyQ® HPV Molecular Analytical Test 53
Xenomics to Introduce Innovative Gender Prediction Test 53
Evogen Unveils New EvoCyclerTM HD12 Molecular Diagnostics System 53
Siemens Healthcare Launches Innovance Antithrombin Test 54
Rosetta Genomics Launches miRview' meso Diagnostic Test 54
ViraCor Laboratories Introduces Cytomegalovirus Antiviral
Resistance Test 55
Abbott Launches Diagnostic Test for HPV Detection 55
Pathwork Diagnostics Introduces Tissue of Origin Test 55
Evogen to Offer Diagnostic Tests 56
Axial Unveils a Test for Detecting AIS 56
Myriad Introduces Prezeon 56
Exiqon Launches Test for Colon Cancer 57
Siemens Launches Diagnostic Tests for Testing Viral Load 57
QIAGEN Launches a Molecular Test for Testing the K-ras Gene 57
Spartan Launches DX-12 DNA Analyzer 58
ViraCor Introduces an Assay for Fungal Infections 58
Illumina Introduces mRNA-Seq 58
QIAGEN Rolls Out a New Diagnostic Test for AIDS 58
QIAGEN Introduces miScript miRNA Inhibitors® and miScript
miRNA Mimics® Test Technologies 59
QIAGEN Introduces New Kits for Gene Expression and Function
Analysis 59
QIAGEN Introduces New Products in EpiTect Product Line 60
QIAGEN Launches QIAsymphony® Novel Modular Platform 60
Q Chip Introduces ReaX' PCR Beads 61
ViraCor Rolls Out a New Test for Detecting Enterovirus 61
TMD Rolls Out New Tests for Colorectal Cancer 61
Gen-Probe Unveils APTIMAR® HPV Tests in Europe 61
Genzyme Genetics Introduces KRAS Mutation Analysis 62
China Medical Develops a Test for Prostate Cancer 62
Palex Medical to Introduce SoftPAP' 62
9. PRODUCT INTRODUCTIONS IN THE RECENT PAST - A PERSPECTIVE BUILDER 63
TMD Launches Test for K-ras Mutations in Colorectal Cancer
Patients 63
CombiMatrix Releases Updated Version of Constitutional Genetic
Array Test 63
Myriad Introduces TheraGuide 5-FU 63
CMDX Unveils First HemeScan' Prognostic 63
CombiMatrix Introduces HemeScan' MDS 63
Genzyme Rolls Out Two New Molecular Tests 64
Dade Behring Launches The Quadriga BeFree 64
BD Diagnostics Introduces The BD Viper System 64
Genzyme Introduces P53 Mutation Analysis 64
CombiMatrix Molecular Diagnostics Rolls Out A New Melanoma Test 64
Global Molecular Diagnostics Industry Page 5/21
6. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Qiagen Launches Fast Cycling PCR Product Line 65
Genzyme Releases Molecular Assay for Colorectal Cancer Patients 65
Roche Diagnostics Launches LightCycler 480 System 65
Roche Diagnostics Introduces AmpliChip CYP450 Test 65
SEQUENOM Unveils iPLEX' 65
SEQUENOM Develops a Novel Process 65
Cerner Corp Develops Cerner Millennium(R) PathNet Helix (TM) 66
Roche Diagnostics Launches Amplicor HPV Test 66
Gen-Probe Launches Procleix Ultrio Assay in Europe 66
Gen-Probe Launches TIGRIS®DTS' System 66
BD Biosciences Introduces BD QZyme' Assay 66
Epoch Biosciences Releases MGB Eclipse' 66
QIAGEN Unveils BioRobot MDx DSP Device 66
Digene Unveils DNAwithPap 67
Exact Sciences Launches Non-Invasive Test for Colorectal Cancer 67
TDT Introduces GCC-B1 Blood Test to Detect Colorectal Cancer 67
AcroMetrix Joins Hands with Nabi to Introduce ViroSure 67
Orchid Cellmark Introduces DNA Express Service 67
Roche Develops New IVD Real-Time PCR Instrument 68
Nanogen Rolls Out First Ever ASR 68
Digene Introduces Hybrid Capture 68
Digene's Hybrid Capture 2 HPV DNA Test to Effectively Identify
Cervical Cancer 68
PGD to Eliminate Human Eggs Affected with Alzheimer's Disease 68
Esoterix Introduces New HCV Testing Program 68
Gen-Probe Releases New APTIMA Combo 2 Assay 69
Nycomed's NeoSpect to Identify Suspected Lung Cancer 69
DNAPrint Introduces New Services to Assist Forensic Market 69
IMBG Develops an Efficient Procedure to Treat Diseases 69
10. RECENT INDUSTRY ACTIVITY 70
Life Technologies Obtains IVD Marking for 7500 Fast Dx PCR
Instrument 70
Xenomics Changes Name to TrovaGene 70
Abbott and GSK Team Up in the Area of Molecular Diagnosis 70
Asuragen Enters Into Collaborations for Pancreatic Cancer Tests 71
Transgenomic Licenses Intellectual Property from Integragen 71
Health Discovery Inks Agreement with Pancreas, Biliary and
Liver Surgery Center of New York 71
Qiagen Enters into Agreement with Celera 72
The Tecan Group Inks Agreement with Enigma 72
AdnaGen AG and TATAA Molecular Diagnostics Inks Agreement 72
Northeast Pharmaceuticals to Establish Biopharma JV with Shenyang 72
Wescor Divests Microarray Technology Related Assets to Gamida
For Life Group 73
Predictive Biosciences Takes Over OncoDiagnostic Laboratory 73
Applied Biosystems Obtains Approval for AmpFlSTR® MiniFiler'
PCR Amplification Kit 74
Life Technologies Acquires AcroMetrix 74
Ipsogen SA and The Institut Curie Enters into Scientific
Global Molecular Diagnostics Industry Page 6/21
7. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Collaboration Agreement 74
bioTheranostics and Ferrer inCode Enters into Commercial
Agreement 74
Quidel Corp Signs Definitive Agreement to Purchase Diagnostic
Hybrids 75
Abbott Obtains CE Marking for New Diagnostic Test 75
Transgenomic Enters into Licensing Agreement with Gene Solutions 75
QIAGEN Acquires SABiosciences 76
Corgenix Medical and BG Medicine Inks Supply Agreement 76
Roche receives FDA Approval for Additional Usage of cobas®
TaqScreen MPX Test 76
Gen-Probe Obtains FDA Approval for Marketing of ProParaflu+TM
Assay 77
bioMerieux Enters into Agreement with GSK 77
Tecan Group and Hologic Sign Agreement 77
QIAGEN Takes Over DxS 78
Tyrian Ends Partnership with Becton, Dickinson and Co 78
Becton, Dickinson and Co to Purchase HandyLab 78
Quidel and BioHelix Enter into Agreement 79
Gen-Probe to Take Over Prodesse 79
Summit Partners Acquires Stake in ApoCell 80
Merck to form Alliance with QIAGEN 80
Gen-Probe to Spin Off Industrial Testing Assets 80
ImClone Systems and Bristol-Myers Squibb Enter into
Collaboration with DxS 80
Danaher to Acquire A Joint Venture Company 81
Abbott Enters into Alliance with Pfizer for Molecular
Diagnostic Test 81
Rosetta and Warnex Ink Distribution Agreement 81
ViraCor Laboratories Merges with IBT Laboratories 82
ELITech Takes Over Assets of Nanogen 82
LabCorp Signs Definitive Agreement with Monogram Biosciences 82
Axial Biotech and University of Utah Enter into Collaboration 82
Celera and Bayer Schering Pharma Sign Licensing Agreement 83
AVESTHAGEN Enters into Collaboration with VTT Technical
Research Centre 83
3M Terminates Collaboration Agreement with Gen-Probe 83
BioGenex and Abbott Expand Joint Development and Distribution
Agreement 84
Pfizer Extends Collaboration Agreement with Monogram Biosciences 84
BD Diagnostics Inks Agreement with HandyLab 84
TriLink BioTechnologies and Osmetech Molecular Diagnostics Ink
Agreement 85
PerkinElmer Buys Analytica of Branford 85
Ipsogen Signs Agreement with Arup Laboratories 86
Prometheus Laboratories and Rosetta Genomics Ink Agreement 86
AMDL and Precision Diagnostic Laboratory Signs Agreement 86
Osmetech Signs Agreement with Fisher HealthCare 87
Interleukin Genetics Inks Licensing Agreement with LABEC Pharma 87
deCODE Genetics Inks Licensing Agreements with Celera 87
Global Molecular Diagnostics Industry Page 7/21
8. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Nuvera Biosciences Signs Licensing Agreement with Veridex 87
GE Healthcare Inks Research Agreement with Brigham and Women's
Hospital 88
Gen-Probe Purchases Tepnel Life Sciences 88
AdnaGen AG Receives US Patent 88
Agilent Technologies Selects Asuragen as Certified Service
Provider 88
Genstruct Enters into Partnership with Gene Logic 89
Lab21 Takes Over Biotec Laboratories 89
ProGenTech and Innovative Biosensors Jointly Sign Extension
Agreement 89
Nanogen Signs and Scandinavian Gene Synthesis Inks Agreement 90
Health Discovery Corporation Inks Licensing Agreement with Abbott 90
BD Diagnostics Receives CE Marking for Amplified DNA Assays 90
Transgenomic Signs Licensing Agreement Power3 Medical Products 91
Rubicon Genomics and Abbott Enter into Licensing Agreement 91
Novartis Extends Collaboration with Gen-Probe 91
Eurogentec Receives ISO-Certification for IVD Oligonucleotides 92
Dako and OSI Pharmaceuticals Enter into Collaboration 92
Combimatrix Molecular Diagnostics and Lenetix Enter into
Partnership 92
Sequenom to Acquire AttoSense' Tests of SensiGen 93
Epigenomics AG and Sysmex Ink Research and Development
Collaboration Deal 93
Gene Express and Biogenuix Medsystems Signs Distribution
Agreement 93
Gene Express and Funakoshi Enter into Distribution Agreement 94
BD and Company Obtains FDA Approval for Marketing GeneOhm'
Cdiff Test 94
XDx and Bristol-Myers Squibb Company Signs Collaborative
Agreement 94
Rosetta Genomics and Teva Pharmaceutical Industries Signs
Distribution Agreement 95
ProGenTech Inks Deal with Center for Disease Control and
Prevention in China 95
National Jewish Health Signs Agreement with Laboratory
Corporation of America Holdings 96
DxS and Amgen Ink Agreement 96
Enigma Diagnostics Inks Term Sheet with Roche Molecular Systems 96
Quintiles Transnational Purchases Targeted Molecular Diagnostics 97
Invitrogen Merges with Applied Biosystems 97
Gen-Probe Receives CE-Mark for APTIMA® HPV Test 97
BD Receives Health Canada Licensing for BD GeneOhm' Cdiff
Molecular Assay 98
Abbott Molecular and Epigenomics Amend Licensing Agreement 98
Nanogen Inks Agreement with A. Menarini Diagnostics 98
EraGen Biosciences Signs Distribution Agreement with Inter Medico 99
Spartan Bioscience Enters into Agreement with NorDiag 99
Celera and Nanogen Extend License Agreement 99
NorDiag and Molzym Enter Into Collaboration and Distribution
Global Molecular Diagnostics Industry Page 8/21
9. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Agreements 100
ZyGEM Inks Agreement with Advalytix Products 100
Response Genetics and NeoGenomics Laboratories Enter into
Agreement 100
SIRS-Lab Obtains Certification for Quality Management of In-
Vitro Diagnostics 100
China Medical and Molecular Diagnostics Technologies Ink
Agreement 101
QIAGEN Takes Over Entire Assets of Biosystems Division of Biotage 102
Cepheid Secures FDA Approval for Xpert' Test 102
Osmetech Signs Agreement with Qiagen 102
Luminex Enters into Agreement with BD Diagnostics 102
bioMérieux Acquires AviaraDx 103
Pall Takes Over GeneSystems 103
Corgenix Medical and BG Medicine Ink Agreement 104
Diatherix Laboratories Receives CLIA Certificate 104
Novartis Diagnostics Secures FDA Authorization for PROCLEIX®
ULTRIO® Assay 104
Bio-Reference Laboratories to Start K-ras Mutation Testing 105
Hologic Purchases Third Wave Technologies 105
Asuragen and Affymetrix Ink an Agreement 105
Health Discovery and DCL Medical Laboratories Sign an Agreement 106
Osmetech Receives the US Food and Drug Administration Clearance 106
BD Diagnostics Secures CE Marking for BD GeneOhmTM Cdiff
molecular Test 107
Siemens Healthcare Diagnostics Secures CE-Marking Approval 107
QIAGEN Takes Over Corbett Life Science 107
QIAGEN Obtains CE Mark Approval for Borrelia and HIV PCR Kits 108
Gen-Probe Receives License from Xceed Molecular 108
Nanogen Bags Contract from US Centers for Disease Control and
Prevention 109
Gen-Probe to Take Over Innogenetics 109
Third Wave Technologies to Buy Intellectual Property 109
Prodesse and Quidel Sign an Agreement 109
Siemens Healthcare Diagnostics Licenses Certain Testing Rights 110
bioMérieux Signs MoU with Foundation for Innovative New
Diagnostics 110
QIAGEN Collaborates with GENEART 110
Agilent Technologies and Agendia to Enter into Partnership 111
Siemens Inks Non-Exclusive Deal with Laboratory Corporation of
America® Holdings 111
BD Diagnostics Receives CE-Marking for BD GeneOhm' VanR Test 111
Health Discovery Completes Trials on Molecular Diagnostic Test
on Prostate Cancer 111
Gen-Probe and Agreement DiagnoCure Amends 2003 License Agreement 112
OccuLogix Purchases Remaining Stake in OcuSense 112
Thermo Fisher Scientific Signs Agreement with Nanogen 113
DCL Medical Laboratories and Third Wave Technologies Enter
into Partnership 113
Gen-Probe Commences Clinical Trial of APTIMA® Assay 113
Global Molecular Diagnostics Industry Page 9/21
10. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Immucor to Buy BioArray Solutions 114
Epigenomics Partners with Abbott Molecular 114
Hitachi High-Technologies and bioMerieux Enter into Partnership 115
Luminex Molecular Diagnostics Signs Agreement with Abbott 115
Abbott Signs Agreement with OSI Pharmaceuticals, Roche and
Genentech 115
Exiqon Takes Over Oncotech 115
Siemens Secures FDA Authorization for VERSANT' 440 Molecular
System 116
Vermillion, Johns Hopkins Ink Agreements to Develop Molecular
Diagnostic Tests 116
Beckman Coulter Inks Licensing Agreements with National
University of Ireland 116
11. CORPORATE ACTIVITY IN THE RECENT PAST - A PERSPECTIVE BUILDER 117
Roche Takes over BioVeris 117
Siemens Acquires Dade Behring 117
DiagnoCure Acquires Catalyst Oncology 117
Burrill & Co Takes over Expression Diagnostics 117
Solis Acquires Bertrand 117
ParagonDx LLC Acquires Gentris Diagnostics 118
Beckman Collaborates to Discover CVD Symptoms 118
Exiqon to Take over Oncotech 118
Roche to Acquire Ventana 118
Qiagen Merges with Digene 118
Qiagen & Bio One Capital Collaborates 119
AGT & MAL Signs MoU 119
Qiagen Obtains Licenses to Real-Time PCR 119
Cepheid Acquires Sangtec 119
Source MDx Collaborates with Pfizer 119
Nanosphere Receives FDA Clearance for Second Molecular
Diagnostic Test 120
QIAGEN Acquires eGene 120
Quest Diagnostics Acquires AmeriPath 120
Mayo and ILMN Team up to Develop Molecular Diagnostics for
Complex Diseases 120
CHEO and ILMN Team up to Develop Molecular Diagnostics for
Newborn Screening 120
Siemens Medical Solutions USA Sets Up Siemens Medical
Solutions Diagnostics 121
Novartis Acquires Chiron 121
Quest Diagnostics Acquires Focus Diagnostics 121
Becton Dickinson Acquires GeneOhm 121
Iris International Acquires Leucadia Technologies 121
Predicant Biosciences Acquires Pathwork Informatics 121
AmeriPath Acquires Rose Pathology Associates 122
Nanogen Acquires Amplimedical's Diagnostics Division 122
Nanogen Acquires Immunoassay Test Business of Spectral
Diagnostics 122
Fisher Scientific Acquires Athena 122
Global Molecular Diagnostics Industry Page 10/21
11. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Qiagen Acquires Genaco 122
Bio-Rad Acquires Blackhawk BioSystems 122
IRIS International Acquires Leucadia Technologies 122
Qiagen Acquires Shenzhen PG Biotech 123
Qiagen Acquires Artus GmbH 123
Nanogen and Fisher Increases Agreement Tenure 123
Qiagen Signs An Agreement with Gentra 123
Qiagen Inks an Agreement with VLA 123
Stratagene Signs an Agreement with AROS 124
Bayer Inks an Agreement with Hamilton Company 124
Prodesse and Invitrogen Sign a Pact 124
Illumina Forms Collaboration with ReaMetrix 124
PerkinElmer Signs an Agreement with Jacobi Medical 124
UniPath and Roche Diagnostics Sign an Accord 124
Qiagen Alliances with Eppendorf 125
Olympus and Cangen Extends their Research Collaboration 125
Toppan, Shimadzu and Third Wave Collaborate to Develop A POC
Molecular Diagnostic Instrument 125
Focus Diagnostics Signs an Agreement with Stratagene 125
Innogenetics Inks an Agreement with Roche Diagnostics 126
The University of Goettingen, Bruker Daltonik and PANATecs
Collaborate to Develop New Molecular Diagnostic Assays for
Rheumatoid Arthritis 126
Focus Diagnostics Enters into an Agreement with Luminex 126
QIAGEN Expands Strategic Alliance with Protedyne 126
Specialty Laboratories Teams Up with SEQUENOM and Siemens 126
Gen-Probe Enters into a Licensing Agreement with Corixa 127
Gen-Probe Inks a Supply and Purchase Agreement with F.
Hoffmann-La Roche 127
Gen-Probe Enters into a Licensing Agreement with AdnaGen 127
Roche Establishes New Polymerase Chain Reaction (PCR)
Manufacturing Center 127
Ambion Establishes a Subsidiary in Japan 127
Gen-Probe Gains FDA Approval for APTIMA® 127
Blood Center of Southeastern Wisconsin Adopts Ambion's
Signature' CF 2.0 ASR 128
Orchid Biosciences, Inc. Becomes Orchid Cellmark Inc 128
Roche Acquires IGEN International 128
GE Takes Over Amersham Plc 128
Nanogen Acquires SYN'X PHARMA 128
Nanogen Merges with Epoch Biosciences 128
Sequenom Enters into Collaboration with Siemens 129
TMD Joins Hands with University of Texas 129
GE Global and Two other Companies Enters into a Joint Research
Collaboration 129
Third Wave and BML Extend Partnership to Promote Molecular
Diagnostic Tests 129
ViroLogic Signs an Agreement with ACLARA 129
Abbott and BioGenex Sign an Agreement 129
Novation Signs a Pact with Bayer Diagnostics 130
Global Molecular Diagnostics Industry Page 11/21
12. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Osmetech Enters into a Licensing Agreement with LGC Limited 130
Licensing Agreement between DxS Ltd and Sangtec Molecular
Diagnostics 130
EraGen Biosciences Strikes a Deal with Inter Medico 130
Nanogen Bags Patent for Molecular Diagnostics and Optical
Waveguides Systems 130
Gen-Probe Secures Regulatory Approval for PROCLEIX ® ULTRIO'
Assay 130
Gen-Probe Bags FDA Approval to Use TIGRIS DTS System for STD
Testing 131
Gen-Probe Acquires Majority Stake in MLT 131
AmeriPath in Strategic Alliance with Roche 131
Abbott and Promega to Offer Nucleic Acid Extraction Products 131
Ambion RNA to Offer Services Through BBI 131
STMicroelectronics Inks an Agreement with Mobidiag 132
BBI Contracts with IDS 132
Focus to Assist FDA in Evaluation of Antimicrobial Resistance 132
Bayer Acquires Rights to Detect HCV and HIV Antibodies 132
Cenetron in Strategic Alliance with Roche 132
Saint Luke's Health System in Alliance with Roche 133
US LABS Adds Gene Expression Profiling Capabilities on (FFPE)
Tissue 133
Bayer Acquires Visible Genetics 133
Qiagen Enters into an Agreement with RMS 133
Dabur Starts a New Molecular Diagnostic Lab 133
Roche Gains Rights for Cervical-Cancer Testing Market 134
Ventana Acquires License From MDI 134
Genzyme Genetics Gains Rights for Genzyme Molecular's Cancer
Diagnostics 134
Abbott in Strategic Alliance with Celera 134
MDI and DiagnoCure Join Hands to Integrate ImmunoCyt/uCyt with
InPath 134
MDI and PMI to Jointly Promote Lung Cancer Detection System 135
MDI in Agreement with Esoterix 135
MDI to Expand Product Base in China 135
Abbott and Tecan to Offer Devices for Molecular Diagnostic Assays 135
Invirion Extends Licensing Agreement with MDI 135
Ambion RNA Grants License to Celera 136
Morewood and IT&M to Introduce New Micro Array System 136
Ambion RNA Constructs New Manufacturing Facility 136
LabCorp Teams up with Celera 136
Athena Launches New DNA Testing for TSC 136
Genezyme Genetics Expands Cancer Testing Services 137
Promega Teams Up with Abbott 137
ChromaVision and Ventana Join Hands to Market Testing Process
that Identifies HPV 137
OraSure in Agreement with Abbott 137
Nanogen and Bionomics to Jointly Develop IVD for Epilepsy 137
DiagnoCure and Compugen Join Hands to Develop Tests to
Identify Epithelial Cancers 137
Global Molecular Diagnostics Industry Page 12/21
13. Find Industry reports, Company profiles
ReportLinker and Market Statistics
OraSure Gets FDA Approval for OraQuick Rapid HIV-1 Test 138
Ampersand and Accumed Merged to Form MDI 138
Abbott Acquires Vysis 138
Millennium and Abbott Forge 5-Year Drug Deal 138
Bode Enters into Agreement to Undertake DNA Testing 139
BD Contracts with TriPath to Develop Molecular Diagnostics 139
TriPath Installs New Interactive System 139
Archemix in Strategic Alliance with RPI 139
AmeriPath Strengthens Relationship with Genomics Collaborative 139
12. FOCUS ON SELECT GLOBAL PLAYERS 140
Abbott Laboratories (US) 140
Abbott Molecular 140
Applera Corp. (US) 140
Celera (US) 140
Biomérieux (France) 141
CytoCore Inc. (US) 141
ELITech Group (France) 142
GE Healthcare (US) 142
Gen-Probe, Inc. (US) 143
Genzyme Corp. (US) 143
Genzyme Genetics (US) 143
MiraiBio, Inc. (US) 144
Novartis Vaccines & Diagnostics, Inc. (US) 144
QIAGEN N.V (The Netherlands) 144
Quest Diagnostics, Inc. (USA) 145
Roche Diagnostics (Switzerland) 145
Siemens Healthcare Diagnostics (US) 146
Tecan Group Ltd. (Switzerland) 146
13. GLOBAL MARKET PERSPECTIVE 147
Table 6: World Recent Past, Current & Future Market Analysis
for Molecular Diagnostics by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan) and Rest of
World Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 147
Table 7: World Historic Review for Molecular Diagnostics by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan) and Rest of World Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2000
through 2006 (includes corresponding Graph/Chart) 148
Table 8: World 11-Year Perspective for Molecular Diagnostics
by Geographic Region - Percentage Breakdown of Dollar Sales
for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan)
and Rest of World Markets for Years 2005, 2010 & 2015
(includes corresponding Graph/Chart) 149
Global Molecular Diagnostics Industry Page 13/21
14. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Table 9: World Recent Past, Current & Future Market Analysis
for Molecular Diagnostics (Infectious Disease Testing) by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), and Rest of World Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2007
through 2015 (includes corresponding Graph/Chart) 150
Table 10: World Historic Review for Molecular Diagnostics
(Infectious Disease Testing) by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific (excluding Japan), and
Rest of World Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2000 through 2006 (includes
corresponding Graph/Chart) 151
Table 11: World 11-Year Perspective for Molecular Diagnostics
(Infectious Disease Testing) by Geographic Region - Percentage
Breakdown of Dollar Sales for US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), and Rest of World Markets for
Years 2005, 2010 & 2015 (includes corresponding Graph/Chart) 152
Table 12: World Recent Past, Current & Future Market Analysis
for Molecular Diagnostics (Pharmacogenomics) by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), and Rest of World Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2007 through 2015
(includes corresponding Graph/Chart) 153
Table 13: World Historic Review for Molecular Diagnostics
(Pharmacogenomics) by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), and Rest of World
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2006 (includes corresponding
Graph/Chart) 154
Table 14: World 11-Year Perspective for Molecular Diagnostics
(Pharmacogenomics) by Geographic Region - Percentage Breakdown
of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), and Rest of World Markets for Years 2005,
2010 & 2015 (includes corresponding Graph/Chart) 155
Table 15: World Recent Past, Current & Future Market Analysis
for Molecular Diagnostics (Cancer Screening) by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), and Rest of World Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2007 through 2015
(includes corresponding Graph/Chart) 156
Table 16: World Historic Review for Molecular Diagnostics
(Cancer Screening) by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan) and Rest of World
Global Molecular Diagnostics Industry Page 14/21
15. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2006 (includes corresponding
Graph/Chart) 157
Table 17: World 11-Year Perspective for Molecular Diagnostics
(Cancer Screening) by Geographic Region - Percentage Breakdown
of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), and Rest of World Markets for Years 2005,
2010 & 2015 (includes corresponding Graph/Chart) 158
14. UNITED STATES 159
A.Market Analysis 159
A Precursor to the Molecular Diagnostics Market in the US 159
Molecular Diagnostics Heavily Tied to Proteomics and Genomics 159
Burgeoning Potential for Genetic Testing 159
Regulatory Environment 160
Regulations Out for Molecular Diagnostic Testing of HPV 160
Limited Reimbursements - A Major Hindrance 161
B.Market Analytics 161
Table 18: The US Recent Past, Current & Future Analysis for
Molecular Diagnostics by Application - Infectious Disease
Testing, Pharmacogenomics, and Cancer Screening Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 161
Table 19: The US Historic Review for Molecular Diagnostics
by Application - Infectious Disease Testing,
Pharmacogenomics, and Cancer Screening Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2006 (includes corresponding Graph/Chart) 162
Table 20: The US 11-Year Perspective for Molecular
Diagnostics by Application - Percentage Breakdown of Dollar
Sales for Infectious Disease Testing, Pharmacogenomics,
andCancer Screening Markets for 2005, 2010 & 2015(includes
corresponding Graph/Chart) 162
15. CANADA 163
Market Analysis 163
Table 21: Canadian Recent Past, Current & Future Analysis
for Molecular Diagnostics by Application - Infectious
Disease Testing, Pharmacogenomics, and Cancer Screening
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) 163
Table 22: Canadian Historic Review for Molecular Diagnostics
by Application - Infectious Disease Testing,
Pharmacogenomics, and Cancer Screening Markets Independently
Global Molecular Diagnostics Industry Page 15/21
16. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2006 (includes corresponding Graph/Chart) 164
Table 23: Canadian 11-Year Perspective for Molecular
Diagnostics by Application - Percentage Breakdown of Dollar
Sales for Infectious Disease Testing, Pharmacogenomics, and
Cancer Screening Markets for 2005, 2010 & 2015 (includes
corresponding Graph/Chart) 164
16. JAPAN 165
Market Analysis 165
Table 24: Japanese Recent Past, Current & Future Analysis
for Molecular Diagnostics by Application - Infectious
Disease Testing, Pharmacogenomics, and Cancer Screening
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) 165
Table 25: Japanese Historic Review for Molecular Diagnostics
by Application - Infectious Disease Testing,
Pharmacogenomics, and Cancer Screening Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2006 (includes corresponding Graph/Chart) 166
Table 26: Japanese 11-Year Perspective for Molecular
Diagnostics by Application - Percentage Breakdown of Dollar
Sales for Infectious Disease Testing, Pharmacogenomics, and
Cancer Screening Markets for 2005, 2010 & 2015 (includes
corresponding Graph/Chart) 166
17. EUROPE 167
A.Market Analysis 167
Insight into Molecular Diagnostics Markets in Europe 167
Table 27: European Molecular Diagnostics Market by Leading
Players (2008) - Market Shares of Leading Players by Value
Sales for Roche Diagnostics, Abbott Diagnostics, Bayer
Diagnostics, Becton Dickinson, Digene Diagnostics,
BioMerieux, and Others (includes corresponding Graph/Chart) 168
B.Market Analytics 169
Table 28: European Recent Past, Current & Future Analysis
for Molecular Diagnostics by Geographic Region - France,
Germany, Italy, UK, and Rest of Europe Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2007 through 2015 (includes corresponding Graph/Chart) 169
Table 29: European Historic Review for Molecular Diagnostics
by Geographic Region - France, Germany, Italy, UK, and Rest
of Europe Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2006 (includes
corresponding Graph/Chart) 170
Global Molecular Diagnostics Industry Page 16/21
17. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Table 30: European 11-Year Perspective for Molecular
Diagnostics by Geographic Region - Percentage Breakdown of
Dollar Sales for France, Germany, Italy, UK, and Rest of
Europe Markets for Years 2005, 2010 & 2015 (includes
corresponding Graph/Chart) 171
Table 31: European Recent Past, Current & Future Analysis
for Molecular Diagnostics by Application - Infectious
Disease Testing, Pharmacogenomics, and Cancer Screening
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) 172
Table 32: European Historic Review for Molecular Diagnostics
by Application -Infectious Disease Testing,
Pharmacogenomics, and Cancer Screening Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2006 (includes corresponding Graph/Chart) 173
Table 33: European 11-Year Perspective for Molecular
Diagnostics by Application - Percentage Breakdown of Dollar
Sales for Infectious Disease Testing, Pharmacogenomics and
Cancer Screening Markets for Years 2005, 2010 & 2015
(includes corresponding Graph/Chart) 174
17a. FRANCE 175
Market Analysis 175
Table 34: French Recent Past, Current & Future Analysis for
Molecular Diagnostics by Application - Infectious Disease
Testing, Pharmacogenomics, and Cancer Screening Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 175
Table 35: French Historic Review for Molecular Diagnostics
by Application - Infectious Disease Testing,
Pharmacogenomics, and Cancer Screening Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2006 (includes corresponding Graph/Chart) 176
Table 36: French 11-Year Perspective for Molecular
Diagnostics by Application - Percentage Breakdown of Dollar
Sales for Infectious Disease Testing, Pharmacogenomics, and
Cancer Screening Markets for 2005, 2010 & 2015 (includes
corresponding Graph/Chart) 176
17b. GERMANY 177
Market Analysis 177
Table 37: German Recent Past, Current & Future Analysis for
Global Molecular Diagnostics Industry Page 17/21
18. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Molecular Diagnostics by Application - Infectious Disease
Testing, Pharmacogenomics, and Cancer Screening Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 177
Table 38: German Historic Review for Molecular Diagnostics
by Application - Infectious Disease Testing,
Pharmacogenomics, and Cancer Screening Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2006 (includes corresponding Graph/Chart) 178
Table 39: German 11-Year Perspective for Molecular
Diagnostics by Application - Percentage Breakdown of Dollar
Sales for Infectious Disease Testing, Pharmacogenomics, and
Cancer Screening Markets for 2005, 2010 & 2015 (includes
corresponding Graph/Chart) 178
17c. ITALY 179
Market Analysis 179
Table 40: Italian Recent Past, Current & Future Analysis for
Molecular Diagnostics by Application - Infectious Disease
Testing, Pharmacogenomics, and Cancer Screening Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 179
Table 41: Italian Historic Review for Molecular Diagnostics
by Application - Infectious Disease Testing,
Pharmacogenomics, and Cancer Screening Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2006 (includes corresponding Graph/Chart) 180
Table 42: Italian 11-Year Perspective for Molecular
Diagnostics by Application - Percentage Breakdown of Dollar
Sales for Infectious Disease Testing, Pharmacogenomics, and
Cancer Screening Markets for 2005, 2010 & 2015 (includes
corresponding Graph/Chart) 180
17d. UNITED KINGDOM 181
Market Analysis 181
Table 43: The UK Recent Past, Current & Future Analysis for
Molecular Diagnostics by Application - Infectious Disease
Testing, Pharmacogenomics, and Cancer Screening Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 181
Table 44: The UK Historic Review for Molecular Diagnostics
by Application - Infectious Disease Testing,
Global Molecular Diagnostics Industry Page 18/21
19. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Pharmacogenomics, and Cancer Screening Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2006 (includes corresponding Graph/Chart) 182
Table 45: The UK 11-Year Perspective for Molecular
Diagnostics by Application - Percentage Breakdown of Dollar
Sales for Infectious Disease Testing, Pharmacogenomics, and
Cancer Screening Markets for 2005, 2010
Global Molecular Diagnostics Industry Page 19/21
20. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Global Molecular Diagnostics Industry
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 4 500.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Global Molecular Diagnostics Industry Page 20/21
21. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Global Molecular Diagnostics Industry Page 21/21